Search
Fortrea Holdings Inc
FTREAdd to Watchlist
17.580USD
+0.180+1.03%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.66BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.03%
5 Days
+3.29%
1 Month
+11.55%
6 Months
+1.91%
Year to Date
+1.91%
1 Year
+237.43%
Key Figures
17.700Open
18.340High
1.57MVolume
LossP/E TTM
16.62P/E Dynamic
--Dividend TTM
1.66%Turnover Ratio
17.400Prev. Close
17.380Low
20.05MTurnover
LossP/E Static
3.16P/B
0.00%Div Yield TTM
-15.40%ROA
18.67052wk High
0.76Volume Ratio
-328.50MNet Profit
94.60MShares
-4.8182EPS TTM
--Beta
-64.55%ROE
3.97052wk Low
5.52%Amplitude
16.31%Gross Margin
1.66BMarket Cap
2.78Reward/Risk
4.78%Risk Rate
TradingKey Stock Score of Fortrea Holdings Inc
Currency: USD Updated: 2026-07-01Key Insights
Fortrea Holdings Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 39 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 16.85.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Fortrea Holdings Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Fortrea Holdings Inc Highlights
StrengthsRisks
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.72B.
Fairly Valued
The company’s latest PE is -3.65, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 98.32M shares, decreasing 20.39% quarter-over-quarter.
Held by Barrow Hanley
Star Investor Barrow Hanley holds 68.09 shares of this stock.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
16.850
Target Price
-3.16%
Upside Space
Fortrea Holdings Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Fortrea Holdings Inc Info
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
Ticker SymbolFTRE
CompanyFortrea Holdings Inc
CEOThakrala (Anshul)
Websitehttps://www.fortrea.com/
Related Instruments
-0.64%
-0.05%
-0.23%
-1.64%
-2.41%
-2.95%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52344.200
+89.900 (+0.17%)
29687.200
-112.100 (-0.38%)
7478.100
+2.600 (+0.04%)
14750.000
-605.000 (-3.94%)
68711.000
-774.000 (-1.11%)
6305.000
+29.600 (+0.47%)
67.404
-0.564 (-0.83%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4063.610
+32.840 (+0.81%)
FAQs
What is the current price of Fortrea Holdings Inc (FTRE)?
The current price of Fortrea Holdings Inc (FTRE) is 17.58.
What is the symbol of Fortrea Holdings Inc?
The ticker symbol of Fortrea Holdings Inc is FTRE.
What is the 52-week high of Fortrea Holdings Inc?
The 52-week high of Fortrea Holdings Inc is 18.67.
What is the 52-week low of Fortrea Holdings Inc?
The 52-week low of Fortrea Holdings Inc is 3.97.
What is the market capitalization of Fortrea Holdings Inc?
The market capitalization of Fortrea Holdings Inc is 1.66B.
Is Fortrea Holdings Inc (FTRE) currently rated as Buy, Hold, or Sell?
According to analysts, Fortrea Holdings Inc (FTRE) has an overall rating of Buy, with a price target of 16.85.
What is the Earnings Per Share (EPS TTM) of Fortrea Holdings Inc (FTRE)?
The Earnings Per Share (EPS TTM) of Fortrea Holdings Inc (FTRE) is -10.81.